Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Mesoblast ( (MESO) ) just unveiled an update.
On March 12, 2026, Mesoblast Limited reported to the U.S. Securities and Exchange Commission that it had lodged a new issue announcement and a change of director’s interest notice with the Australian Securities Exchange. The filing detailed changes in the securities holdings of director Gregory George over March 3–6, 2026, including on-market purchases of ordinary shares and American Depositary Shares, and conversions of ordinary shares into ADS without altering his underlying economic interest.
Following these transactions, George’s indirect interests shifted, with 5,644,192 ordinary shares and 14,415,410 ADS held indirectly, alongside existing direct holdings and warrants. While the moves primarily reflect portfolio adjustments and increased exposure by an insider rather than an operational shift, they provide investors with transparency on board-level confidence and align with regulatory obligations in both Australia and the United States.
The most recent analyst rating on (MESO) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Mesoblast stock, see the MESO Stock Forecast page.
Spark’s Take on MESO Stock
According to Spark, TipRanks’ AI Analyst, MESO is a Neutral.
The score is held back primarily by weak financial performance (ongoing losses and cash outflows) and soft technical momentum. These are partially offset by a positive earnings-call outlook, including raised commercial evidence for Ryoncil (strong H1 revenue contribution, 93% gross margin) and clear revenue guidance, while valuation signals are limited due to an unusable P/E and no dividend.
To see Spark’s full report on MESO stock, click here.
More about Mesoblast
Mesoblast Limited is an Australia-based biotechnology company focused on developing and commercializing regenerative medicine therapies, including advanced cellular medicines derived from mesenchymal lineage cells. The company targets serious inflammatory and cardiovascular conditions and is listed on both the Australian Securities Exchange and in the U.S. via American Depositary Shares.
Average Trading Volume: 239,118
Technical Sentiment Signal: Hold
Current Market Cap: $1.95B
Find detailed analytics on MESO stock on TipRanks’ Stock Analysis page.